Eugene A Konorev
Overview
Explore the profile of Eugene A Konorev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cobb M, Tao S, Shortt K, Girgis M, Hauptman J, Schriewer J, et al.
Am J Physiol Heart Circ Physiol
. 2022 Oct;
323(6):H1091-H1107.
PMID: 36269647
Many anticancer therapies cause serious cardiovascular complications that degrade quality of life and cause early mortality in treated patients. Specifically, doxorubicin is known as an effective anticancer agent that causes...
2.
Sun Z, Schriewer J, Tang M, Marlin J, Taylor F, Shohet R, et al.
J Mol Cell Cardiol
. 2015 Dec;
90:129-38.
PMID: 26686989
Elevated ALK4/5 ligands including TGF-β and activins have been linked to cardiovascular remodeling and heart failure. Doxorubicin (Dox) is commonly used as a model of cardiomyopathy, a condition that often...
3.
Kumar S, Konorev E, Aggarwal D, Kalyanaraman B
J Proteomics
. 2011 Feb;
74(5):683-97.
PMID: 21338723
Doxorubicin-induced cardiomyopathy in cancer patients is well established. The proposed mechanism of cardiac damage includes generation of reactive oxygen species, mitochondrial dysfunction and cardiomyocyte apoptosis. Exposure of adult rat cardiomyocytes...
4.
Chandran K, Aggarwal D, Migrino R, Joseph J, McAllister D, Konorev E, et al.
Biophys J
. 2009 Feb;
96(4):1388-98.
PMID: 19217856
Doxorubicin (DOX) is used for treating various cancers. Its clinical use is, however, limited by its dose-limiting cardiomyopathy. The exact mechanism of DOX-induced cardiomyopathy still remains unknown. The goals were...
5.
Konorev E, Vanamala S, Kalyanaraman B
Free Radic Biol Med
. 2008 Oct;
45(12):1723-8.
PMID: 18926904
A proposed mechanism for the cardiotoxicity of doxorubicin (DOX) involves apoptosis in cardiomyocytes. In the study described here, we investigated the molecular basis for the differences in DOX-induced toxicity in...
6.
Kalivendi S, Konorev E, Cunningham S, Vanamala S, Kaji E, Joseph J, et al.
Biochem J
. 2005 Apr;
389(Pt 2):527-39.
PMID: 15799720
Doxorubicin (DOX), a widely used antitumour drug, causes dose-dependent cardiotoxicity. Cardiac mitochondria represent a critical target organelle of toxicity during DOX chemotherapy. Proposed mechanisms include generation of ROS (reactive oxygen...
7.
Wang S, Konorev E, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B
J Biol Chem
. 2004 Apr;
279(24):25535-43.
PMID: 15054096
Doxorubicin (DOX), a widely used chemotherapeutic agent, exhibits cardiotoxicity as an adverse side effect in cancer patients. DOX-mediated cardiomyopathy is linked to its ability to induce apoptosis in endothelial cells...
8.
Pieper G, Halligan N, Hilton G, Konorev E, Felix C, Roza A, et al.
Proc Natl Acad Sci U S A
. 2003 Mar;
100(6):3125-30.
PMID: 12624190
We examined iron nitrosylation of non-heme protein and enzymatic activity of the Fe-S cluster protein, aconitase, in acute cardiac allograft rejection. Heterotopic transplantation of donor hearts was performed in histocompatibility...
9.
Konorev E, Kotamraju S, Zhao H, Kalivendi S, Joseph J, Kalyanaraman B
Free Radic Biol Med
. 2002 Oct;
33(7):988.
PMID: 12361808
The cytoprotective effects of redox-active metalloporphyrins (e.g., FeTBAP and MnTBAP) were generally attributed to their ability to scavenge reactive oxygen and nitrogen species. In this study, we evaluated the pro-...